Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

Eli Lilly (LLY) PT Lowered to $92 at Jefferies; Reiterates Buy

April 26, 2017 9:10 AM EDT

Jefferies lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $94.00) while maintaining a Buy rating. Jefferies lowered EPS estimates by up to 7% mid term and are now mostly in line with consensus over the next few years.

Jefferies' revenue estimates... More